SGN-STNV for Cancer

Recruiting in Palo Alto (17 mi)

+21 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Seagen Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

Research Team

Suzanne McGoldrick, MD

Principal Investigator

Seagen Inc.

Eligibility Criteria

This trial is for adults with certain advanced solid tumors like breast, lung, ovarian, and cervical cancers that have not responded to standard treatments or if the patient cannot tolerate them. Participants must have measurable disease, be in good physical condition (ECOG score of 0 or 1), and have normal organ function. People with a recent history of other cancers, brain metastases, meningitis cancer-related, previous treatment with MMAE drugs, significant neuropathy or uncontrolled serious infections are excluded.

Inclusion Criteria

My condition has not improved with standard treatments or I cannot tolerate them.

Participants must have a tumor in a specific location that meets certain requirements.

My breast cancer is not HER2 positive.

See 8 more

Exclusion Criteria

I have not had another cancer or any signs of cancer in the last 3 years.

I do not have severe nerve pain or damage.

I have previously been treated with drugs containing MMAE.

See 3 more

Treatment Details

Interventions

SGN-STNV (Monoclonal Antibodies)

Trial OverviewSGN-STNV is being tested for safety and effectiveness in treating various types of solid tumors. The study has two parts: Part A determines the right dose to give patients; Part B uses this dose to further evaluate safety and how well SGN-STNV works against specific tumor types.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: SGN-STNVExperimental Treatment1 Intervention

SGN-STNV monotherapy